Riskpilot← Back to searchSign inGet full accessTESARO Bio Sweden AB
ABIn liquidationOrg 5591018824Business and other management consultancy activities · NACE 7022Est. 20170 employees
Revenue 2020
SEK 0
EBITDA margin
—
-121% vs 2019
Equity ratio
49.9%
Financial strength
Net profit 2020
SEK -816K
-139% vs 2019
| Revenue | SEK 0 | — |
| EBITDA | SEK -728K | -121% |
| Net profit | SEK -816K | -139% |
| Total assets | SEK 2,7M | -86% |
| Equity | SEK 1,3M | -90% |
| Employees | 0 | — |
Legal name
TESARO Bio Sweden AB
Org number
5591018824
Legal form
Aktiebolag
NACE code
7022 · Business and other management consultancy activities
Founded
22 februari 2017
Share capital
SEK 0
Employees
0
VAT registered
No
Audit selected
No
Last report
2020-12-31
Financial year
January – December
Company purpose
Bolaset skall förvärva, utveckla och distribuera biofarmaceutiska produkter, substanser och teknik för användning inom onkologi samt bedriva därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|
| Revenue | 8 575 | 19 381 | 37 578 | 0 |
| Staff expenses | — | — | — | — |
| EBITDA | 305 | 673 | 3 411 | −728 |
| Depreciation & amort. | −0 | −0 | −0 | −0 |
| EBIT | 305 | 673 | 3 411 | −728 |
| Net financials | 32 | −180 | −612 | −74 |
| Profit before tax | 271 | 494 | 2 800 | −816 |
| Tax | −108 | −148 | −701 | −0 |
| Net profit | 163 | 346 | 2 099 | −816 |
| Item | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|
| Total assets | 8 606 | 16 925 | 19 715 | 2 701 |
| Equity | 5 313 | 10 938 | 13 037 | 1 348 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 3 294 | 5 987 | 6 678 | 1 353 |
| Total debt | 3 294 | 5 987 | 6 678 | 1 353 |
EBITDA margin
-72800000.0%
This company
15.8%
Market median
-460759594% vs market
20172020
Equity ratio
49.9%
This company
38.2%
Market median
+31% vs market
20172020
Return on equity
-60.5%
This company
18.4%
Market median
-429% vs market
20172020
Net profit margin
-81600000.0%
This company
8.1%
Market median
-1007407507% vs market
20172020
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20172020
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
20172020
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-02-01 – 2017-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AM Chief Auditor | Chief Auditor | 2020 |
JM Liquidator | Liquidator | 2020 |
| Former (2) | ||
MJ External Signatory | External Signatory | 2020 – 2022 |
JK External Signatory | External Signatory | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
| Deputy Board Member | 2020 – 2022 | |
| Board of Directors | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of TESARO Bio Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Monika Jasinska-Janusz | External Signatory | 0 companies |
| Alexandros Martin Kouvatsos | Chief Auditor | 0 companies |
| Jing Koon Chin | External Signatory | 0 companies |
| Jenny Maria Hildén | Liquidator | 0 companies |
| Tetiana Luczkiw | Deputy Board Member | 0 companies |
| Nils-Erik Niclas Källbom Karlsson | Board of Directors | 0 companies |